Akero Therapeutics Accounts Payable

Akero Therapeutics (AKRO) currently reports a accounts payable of $20M as of September 2025. That compares with $25M in the prior-year period — down 19.1% year over year. Use the charts on this page to explore Akero Therapeutics's accounts payable history and peer comparisons.

Akero Therapeutics's accounts payable decreased from $25M to $20M — a 19.1% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akero Therapeutics reported $20M in accounts payable as of September 2025. That compares with $25M in the prior-year period — down 19.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Akero Therapeutics, and consider following AKRO for alerts when major investors trade the stock.

Akero Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AKRO with unrelated industries.